Iqvia Holdings Inc (IQV)

$228.18 +3.28 (1.46%)
Market Cap 38.30B
Revenue (ttm) 15.41B
Net Income (ttm) 1.37B
EPS (ttm) N/A
PE Ratio 20.62
Forward PE 20.13
Profit Margin 8.91%
Debt to Equity Ratio 2.38
Volume 1,666,100
Avg Vol 1,549,852
Day's Range N/A - N/A
Shares Out 170.30M
Stochastic %K 96%
Beta 1.34
Analysts Strong Sell
Price Target $244.38

Company Profile

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions th...

Industry: Diagnostics & Research
Sector: Healthcare
Phone: 919 998 2000
Address:
2400 Ellis Road, Durham, United States
Joshua_X
Joshua_X Nov. 25 at 1:31 PM
Life Science Tools — Early Stabilization? Post: Some signs of stabilization in R&D spending. $IQV and $WAT showing relative strength. Keeping $PACB on watch for long-term innovation. Any other life-science names on your radar?
0 · Reply
Iightning
Iightning Nov. 25 at 10:41 AM
1ightning® Options Trade Alert (Actionable) | Buy $IQV Dec 19 $230 Call | Enter: $5.88 Exit: $9.24 | Profit: 57.23% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 24 at 11:36 PM
1ightning® Options Trade Alert (Actionable) | Buy $IQV Dec 19 $230 Call | Enter: $5.88 Exit: $9.24 | Profit: 57.23% ROI | https://1ightning.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 22 at 9:13 PM
$IPAR $IQV $IREN $IRMD $IRS
0 · Reply
Iightning
Iightning Nov. 21 at 8:54 PM
1ightning® Options Trade Alert (Actionable) | Buy $IQV Dec 19 $220 Call | Enter: $7.28 Exit: $12.89 | Profit: 77.14% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 20 at 11:46 PM
1ightning® Options Trade Alert (Actionable) | Buy $IQV Dec 19 $220 Call | Enter: $7.28 Exit: $12.89 | Profit: 77.14% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 9:26 PM
1ightning® Options Trade Alert (Actionable) | Buy $IQV Dec 19 $220 Call | Enter: $7.28 Exit: $12.89 | Profit: 77.14% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 5:52 AM
1ightning® Options Trade Alert (Actionable) | Buy $IQV Dec 19 $220 Call | Enter: $7.28 Exit: $12.89 | Profit: 77.14% ROI | https://1ightning.com
0 · Reply
RunnerSignals
RunnerSignals Nov. 13 at 9:27 PM
sideways no more $CLBT $BWEN $VGZ $ORLA $IQV all snapped out of their sleepy ranges and popped above their short term averages today
0 · Reply
StockConsultant
StockConsultant Nov. 13 at 2:47 PM
$IQV IQVIA stock, watch for a top of range breakout at https://stockconsultant.com/?IQV
0 · Reply
Latest News on IQV
Oakmark Global Concentrated Strategy Q3 2025 Top Contributors And Detractors

Nov 12, 2025, 5:43 AM EST - 13 days ago

Oakmark Global Concentrated Strategy Q3 2025 Top Contributors And Detractors

BABA CHTR CNC CNH GOOG GOOGL

IQVIA Holdings Inc. (IQV) Presents at UBS Global Healthcare Conference 2025 Transcript

Nov 11, 2025, 2:31 PM EST - 13 days ago

IQVIA Holdings Inc. (IQV) Presents at UBS Global Healthcare Conference 2025 Transcript

Oakmark Concentrated Strategy: 6 Stocks That Raised Guidance And Drove Innovation

Nov 7, 2025, 2:15 AM EST - 18 days ago

Oakmark Concentrated Strategy: 6 Stocks That Raised Guidance And Drove Innovation

CRM GOOG GOOGL KDP MOH WBD

Dr. William G. Kaelin Jr. joins IQVIA Board of Directors

Nov 5, 2025, 4:15 PM EST - 19 days ago

Dr. William G. Kaelin Jr. joins IQVIA Board of Directors

IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript

Oct 28, 2025, 1:52 PM EDT - 4 weeks ago

IQVIA Holdings Inc. (IQV) Q3 2025 Earnings Call Transcript

IQVIA narrows annual profit forecast amid continued research contract cancellations

Oct 28, 2025, 7:53 AM EDT - 4 weeks ago

IQVIA narrows annual profit forecast amid continued research contract cancellations

IQVIA Reports Third-Quarter 2025 Results

Oct 28, 2025, 7:00 AM EDT - 4 weeks ago

IQVIA Reports Third-Quarter 2025 Results

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

Oct 24, 2025, 4:30 AM EDT - 4 weeks ago

Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning

APD CNC COF FISV IVZ JNJ LRCX

IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025

Oct 21, 2025, 4:15 PM EDT - 4 weeks ago

IQVIA CEO Ari Bousbib to Speak at UBS Global Healthcare Conference on November 11, 2025

IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025

Sep 30, 2025, 4:15 PM EDT - 7 weeks ago

IQVIA to Announce Third-Quarter 2025 Results on October 28, 2025

ILMN Stock vs. IQV Stock

Sep 26, 2025, 9:40 AM EDT - 2 months ago

ILMN Stock vs. IQV Stock

ILMN

IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships

Sep 16, 2025, 8:00 AM EDT - 2 months ago

IQVIA Receives WCG Pinnacle Award for Excellence in Site Relationships

IQVIA: A Positive Long-Term Outlook Despite Trump Legislation

Sep 11, 2025, 2:00 AM EDT - 2 months ago

IQVIA: A Positive Long-Term Outlook Despite Trump Legislation

IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management

Sep 10, 2025, 8:00 AM EDT - 2 months ago

IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management

IQVIA names Michael Fedock as financial chief

Sep 2, 2025, 9:41 AM EDT - 3 months ago

IQVIA names Michael Fedock as financial chief

IQVIA Announces CFO Transition in Early 2026

Sep 2, 2025, 9:00 AM EDT - 3 months ago

IQVIA Announces CFO Transition in Early 2026

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

Aug 28, 2025, 8:00 AM EDT - 3 months ago

IQVIA and Flagship Pioneering Announce Strategic Collaboration to Accelerate the Development of Breakthrough Life Sciences Companies

FHTX MRNA SANA

The Big 3: BLDR, IQV, LOW

Aug 19, 2025, 12:00 PM EDT - 3 months ago

The Big 3: BLDR, IQV, LOW

BLDR LOW

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

Aug 18, 2025, 9:00 AM EDT - 3 months ago

IQVIA and Veeva Announce Long-term Clinical and Commercial Partnerships and Resolution of All Disputes

VEEV

IQVIA: Q2 Earnings Exceeded My Expectations

Jul 22, 2025, 5:40 PM EDT - 4 months ago

IQVIA: Q2 Earnings Exceeded My Expectations

IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript

Jul 22, 2025, 2:00 PM EDT - 4 months ago

IQVIA Holdings Inc. (IQV) Q2 2025 Earnings Call Transcript

IQVIA beats quarterly estimates on resilient demand for healthcare analytics

Jul 22, 2025, 8:42 AM EDT - 4 months ago

IQVIA beats quarterly estimates on resilient demand for healthcare analytics

IQVIA Reports Second-Quarter 2025 Results

Jul 22, 2025, 7:00 AM EDT - 4 months ago

IQVIA Reports Second-Quarter 2025 Results

IQVIA: Competition Is Creating More Challenges Over The Long Haul

Jul 16, 2025, 7:54 AM EDT - 4 months ago

IQVIA: Competition Is Creating More Challenges Over The Long Haul

IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

Jul 1, 2025, 7:00 AM EDT - 5 months ago

IQVIA to Announce Second-Quarter 2025 Results on July 22, 2025

IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement'

Jun 16, 2025, 9:00 AM EDT - 5 months ago

IQVIA Health Research Space Wins 2025 MedTech Breakthrough Award for ‘Best Mobile App for Patient Engagement'

IQVIA Launches New AI Agents for Life Sciences and Healthcare

Jun 11, 2025, 7:00 AM EDT - 5 months ago

IQVIA Launches New AI Agents for Life Sciences and Healthcare

IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?

Jun 10, 2025, 2:23 PM EDT - 5 months ago

IQVIA Stock: Stuck In A Time Spiral - Value Play Or Bull Trap?

IQVIA Announces Pricing of Senior Notes

Jun 2, 2025, 4:37 PM EDT - 6 months ago

IQVIA Announces Pricing of Senior Notes

IQVIA Announces Offering of Senior Notes

Jun 2, 2025, 8:10 AM EDT - 6 months ago

IQVIA Announces Offering of Senior Notes

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

May 27, 2025, 7:00 AM EDT - 6 months ago

Rein Therapeutics Announces First Patient Dosed in RENEW Phase 2 Trial of LTI-03 in Patients with IPF

RNTX

IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

May 16, 2025, 8:00 AM EDT - 6 months ago

IQVIA and SCRI Collaborate to Accelerate Global Oncology Trials

IQVIA: Q1 Earnings Support Steady Optimism

May 9, 2025, 1:48 PM EDT - 7 months ago

IQVIA: Q1 Earnings Support Steady Optimism

IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13

May 7, 2025, 4:15 PM EDT - 7 months ago

IQVIA CFO Ron Bruehlman to speak at the Bank of America Annual Health Care Conference on May 13

IQVIA Holdings Inc. (IQV) Q1 2025 Earnings Call Transcript

May 6, 2025, 3:04 PM EDT - 7 months ago

IQVIA Holdings Inc. (IQV) Q1 2025 Earnings Call Transcript

IQVIA Reports First-Quarter 2025 Results

May 6, 2025, 7:00 AM EDT - 7 months ago

IQVIA Reports First-Quarter 2025 Results

IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards

Apr 28, 2025, 9:00 AM EDT - 7 months ago

IQVIA celebrates Marie E. Lamont and Dr. Joanne Hackett, winners of Healthcare Businesswomen's Association Awards

IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm

Apr 23, 2025, 9:00 AM EDT - 7 months ago

IQVIA named a front-runner in generative AI innovation by global industry research and analysis firm

IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

Apr 21, 2025, 4:15 PM EDT - 7 months ago

IQVIA to Announce First-Quarter 2025 Results on May 6, 2025

Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report

Apr 15, 2025, 8:00 AM EDT - 8 months ago

Stabilization and improvement seen in multiple key biopharma R&D metrics, says IQVIA Institute Report

IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services

Mar 10, 2025, 9:00 AM EDT - 9 months ago

IQVIA recognized as a leader in IDC MarketScape's 2024 assessment for decentralized clinical trial technologies and consulting services

IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials

Mar 4, 2025, 9:00 AM EST - 9 months ago

IQVIA Laboratories launches Site Lab Navigator with breakthrough e-Requisition innovation to transform clinical trials

Global Healthy Living Foundation and IQVIA Institute Report Millions of Adult Vaccines Likely Missed When States Restrict Pharmacist Participation

Feb 25, 2025, 3:00 PM EST - 9 months ago

Global Healthy Living Foundation and IQVIA Institute Report Millions of Adult Vaccines Likely Missed When States Restrict Pharmacist Participation

IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence

Feb 24, 2025, 9:00 AM EST - 9 months ago

IQVIA AI Assistant wins 2024 PM360 Innovation Award for Artificial Intelligence

IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025

Feb 21, 2025, 9:00 AM EST - 9 months ago

IQVIA CFO Ron Bruehlman to Speak at the TD Cowen Annual Health Care Conference on March 4, 2025

IQVIA Releases 2024 Sustainability Report

Feb 20, 2025, 10:06 AM EST - 9 months ago

IQVIA Releases 2024 Sustainability Report

IQVIA: Revenues, Net Profit Margin, And A Positive Long-Term Outlook Will Pave The Way

Feb 16, 2025, 3:36 AM EST - 10 months ago

IQVIA: Revenues, Net Profit Margin, And A Positive Long-Term Outlook Will Pave The Way

IQVIA Holdings Inc. (IQV) Q4 2024 Earnings Call Transcript

Feb 6, 2025, 11:58 AM EST - 10 months ago

IQVIA Holdings Inc. (IQV) Q4 2024 Earnings Call Transcript

IQVIA Delivers Solid Q4 Growth Despite 'Choppy' Market Conditions

Feb 6, 2025, 11:37 AM EST - 10 months ago

IQVIA Delivers Solid Q4 Growth Despite 'Choppy' Market Conditions

IQVIA beats quarterly results estimates on analytics services demand

Feb 6, 2025, 8:34 AM EST - 10 months ago

IQVIA beats quarterly results estimates on analytics services demand

Joshua_X
Joshua_X Nov. 25 at 1:31 PM
Life Science Tools — Early Stabilization? Post: Some signs of stabilization in R&D spending. $IQV and $WAT showing relative strength. Keeping $PACB on watch for long-term innovation. Any other life-science names on your radar?
0 · Reply
Iightning
Iightning Nov. 25 at 10:41 AM
1ightning® Options Trade Alert (Actionable) | Buy $IQV Dec 19 $230 Call | Enter: $5.88 Exit: $9.24 | Profit: 57.23% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 24 at 11:36 PM
1ightning® Options Trade Alert (Actionable) | Buy $IQV Dec 19 $230 Call | Enter: $5.88 Exit: $9.24 | Profit: 57.23% ROI | https://1ightning.com
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 22 at 9:13 PM
$IPAR $IQV $IREN $IRMD $IRS
0 · Reply
Iightning
Iightning Nov. 21 at 8:54 PM
1ightning® Options Trade Alert (Actionable) | Buy $IQV Dec 19 $220 Call | Enter: $7.28 Exit: $12.89 | Profit: 77.14% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 20 at 11:46 PM
1ightning® Options Trade Alert (Actionable) | Buy $IQV Dec 19 $220 Call | Enter: $7.28 Exit: $12.89 | Profit: 77.14% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 9:26 PM
1ightning® Options Trade Alert (Actionable) | Buy $IQV Dec 19 $220 Call | Enter: $7.28 Exit: $12.89 | Profit: 77.14% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 5:52 AM
1ightning® Options Trade Alert (Actionable) | Buy $IQV Dec 19 $220 Call | Enter: $7.28 Exit: $12.89 | Profit: 77.14% ROI | https://1ightning.com
0 · Reply
RunnerSignals
RunnerSignals Nov. 13 at 9:27 PM
sideways no more $CLBT $BWEN $VGZ $ORLA $IQV all snapped out of their sleepy ranges and popped above their short term averages today
0 · Reply
StockConsultant
StockConsultant Nov. 13 at 2:47 PM
$IQV IQVIA stock, watch for a top of range breakout at https://stockconsultant.com/?IQV
0 · Reply
JarvisFlow
JarvisFlow Nov. 13 at 10:44 AM
BMO Capital has updated their rating for IQVIA Hldgs ( $IQV ) to Outperform with a price target of 260.
0 · Reply
theflynews
theflynews Nov. 7 at 4:21 PM
Private Markets: Anthropic projects $70B in revenue in 2028 - $IQV - https://thefly.com/permalinks/entry.php/IQVid4234907?1762532330C38
0 · Reply
SuperGreenToday
SuperGreenToday Nov. 5 at 7:40 PM
$IQV Share Price: $210.68 Contract Selected: May 15, 2026 $210 Calls Buy Zone: $19.55 – $24.15 Target Zone: $31.14 – $38.06 Potential Upside: 50% ROI Time to Expiration: 190 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
RunnerSignals
RunnerSignals Nov. 5 at 4:45 AM
Dip but not done yet $NEE $RTX $DHR $IQV $BTDR all cooling off but still flexing that uptrend muscle. are these just breathers before the next bounce?
1 · Reply
NVDAMillionaire
NVDAMillionaire Nov. 3 at 4:54 PM
$IQV Great piece that accurately captures IQV's current position. So if you want to refresh your understanding of IQV or learn about IQV for the first time, this is essential reading. https://beyondspx.com/quote/IQV/analysis/iqvia-s-intelligent-evolution-ai-diversification-and-a-resilient-growth-path-nyse-iqv
0 · Reply
JarvisFlow
JarvisFlow Nov. 3 at 4:18 PM
TD Cowen updates rating for IQVIA Hldgs ( $IQV ) to Hold, target set at 206 → 215.
0 · Reply
IN0V8
IN0V8 Oct. 31 at 7:31 PM
$IQV Buy Mizuho raises target price to $250 from $225
0 · Reply
SuperGreenToday
SuperGreenToday Oct. 31 at 5:59 PM
$IQV Share Price: $215.32 Contract Selected: May 15, 2026 $220 Calls Buy Zone: $18.45 – $22.79 Target Zone: $33.33 – $40.74 Potential Upside: 71% ROI Time to Expiration: 195 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
PickAlpha
PickAlpha Oct. 30 at 11:35 AM
pt 3/6: Thermo Fisher to acquire Clario for up to $9.4BN (incl. earnout & deferred), expanding clinical-trial tech/biopharma services $TMO $IHI $IQV $XHE
0 · Reply
erevnon
erevnon Oct. 29 at 6:58 PM
UBS maintains IQVIA Hldgs $IQV at Buy and raises the price target from $225 to https://marketsblock.com/stock-upgrades-and-downgrades/
0 · Reply
ZacksResearch
ZacksResearch Oct. 28 at 6:10 PM
$IQV just delivered a clean beat across the board 💥 Earnings and revenues topped estimates in Q3, with year-over-year growth strong across every key segment — plus a full-year guidance hike signals confidence heading into year-end. Full breakdown here 👉 https://www.zacks.com/stock/news/2779391/iqvia-earnings-revenues-beat-estimates-in-q3-increase-yy?cid=sm-stocktwits-2-2779391-teaser-18125&ADID=SYND_STOCKTWITS_TWEET_2_2779391_TEASER_18125
0 · Reply
ZacksResearch
ZacksResearch Oct. 28 at 5:10 PM
$IQV beats earnings & revenue estimates — but is it enough? 🤔 IQVIA posted a 5.6% YoY EPS rise and outperformed the Zacks Consensus Estimate by 1.4%. Revenues grew 5.2% YoY, yet it carries a Zacks Rank #4 (Sell). Complete breakdown here 👉 https://www.zacks.com/stock/news/2779391/iqvia-earnings-revenues-beat-estimates-in-q3-increase-yy?cid=sm-stocktwits-2-2779391-body-18126&ADID=SYND_STOCKTWITS_TWEET_2_2779391_BODY_18126
0 · Reply